The clinical and bacteriological factors for optimal levofloxacin- containing triple therapy in second-line Helicobacter pylori eradication

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Tai, Wei Chen ^a   Lee, Chen Hsiang ^a   Chiou, Shue Shian ^a   Kuo, Chung Mou ^a   Kuo, Chung Huang ^a   Liang, Chih Ming ^a   Lu, Ng Sheng ^a   Chiu, Chien Hua ^b   Wu, Keng Liang ^a   Chiu, Yi Chun ^a   Hu, Tsung I ^a   Chuah, Seng Kee ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; LEVOFLOXACIN; PROTON PUMP INHIBITOR; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL STRAIN; BACTERIUM CULTURE; CLINICAL PROTOCOL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; FEMALE; FOLLOW UP; HEADACHE; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; RASH; TREATMENT DURATION; VOMITING; AGED; CONTROLLED CLINICAL TRIAL; DRUG EFFECTS; GENETICS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MIDDLE AGED;

ADULT; AGED; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LEVOFLOXACIN; MALE; MIDDLE AGED;

EID: 84930631224     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105822     Document Type: Article

References (39)

1. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, et al. (2012) Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut; 61: 646-664.
2. Kiesslich R (2008) Does treatment with levofloxacine improve eradication of Helicobacter pylori? Z Gastroenterol. 2008; 46: 83-84.
3. Güzelbulut F, Sezikli M, Akkan, Erhan Altunöz M, Günes P, et al. (2011) Application of levofloxacine in the second phase of sequential therapy regimen for Helicobacter pylori eradication: is it a good choice? Minerva Med. 102: 171-176.
4. Chuah SK, Tsay FW, Hsu PI, Wu DC (2011) A new look at anti-Helicobacter pylori therapy. World J Gastroenterol. 17: 3971-3975.
5. Gisbert JP (2012) Rescue Therapy for Helicobacter pylori Infection 2012. Gastroenterol Res Pract. 2012: 974594.
6. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, et al. (2009) Second Asia-Pacific Conference. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 24: 1587-1600.
7. Gisbert JP, Morena F (2006) Systematic review and meta-analysis: Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 23: 35-44. (Pubitemid 43381164)
8. Gisbert JP, Bermejo F, Castro-Fernández M, Perez-Aisa A, Fenandez-Bermejo M, et al. (2008) Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol. 103: 71-76.
9. Gisbert JP, Pérez-Aisa A, Bermejo F, Castro-Fernandez M, Almela P, et al. (2013) Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. J Clin Gastroenterol. 2013; 47: 130-135.
10. Bilardi C, Dulbecco P, Zentilin P, Reglioni S, Liritano E, et al. (2004) A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol 2004; 2: 997-1002. (Pubitemid 39539749)
11. O'Connor A, Molina-Infante J, Gisbert JP, O'Morain C (2013) Treatment of Helicobacter pylori infection 2013. Helicobacter. 18 Suppl 1: 58-65.
12. Chuah SK, Hsu PI, Chang KC, Chiu YC, Wu KL, et al. (2012) Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori. Helicobacter. 17: 216-223.
13. Graham DY, Lu H, Yamaoka Y (2007) A report card to grade Helicobacter pylori therapy. Helicobacter 12; 275-8. (Pubitemid 47196342)
14. Kuo CH, Hsu PI, Kuo FC, Wang SS, Hu HM, et al. (2013) Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial. J Antimicrob Chemother. 68: 222-228.
15. Hsu PI, Chen WC, Tsay FW (2014) Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy. Helicobacter. 19: 74-79.
16. Hsu PI, Hwang IR, Cittelly D, Lai KH, El-Zimaity HM, et al. (2002) Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island. Am J Gastroenterol 97: 2231-2238.
17. Sánchez JE, Sáenz NG, Rincón MR, Martin IT, Sánchez EG, et al. (2000) "Susceptibility of Helicobacter pylori to mupirocin, oxazolidionones, quinupristin/dalfopristin and new quinolones," J Antimicrob Chemother. 46: 283-285.
18. Tanaka M, Isogai E, Isogai H, Hayashi S, Hirose K, et al. (2002) "Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori," J Antimicrob Chemother 49: 1039-1040. (Pubitemid 34692903)
19. Antos D1, Schneider-Brachert W, Bästlein E, Hänel C, Haferland C, et al. (2006) "7-Day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity," Helicobacter 11: 39-45.
20. Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, et al. (2012) The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment-a pilot study. Helicobacter. 17: 374-381.
21. Miehlke S, Krasz S, Schneider-Brachert W, Kuhlisch E, Berning M, et al. (2011) Randomized days of esomeprazole, moxifloxacin, and amoxicillin for trial on 14 versus 7 second-line or rescue treatment of Helicobacter pylori infection. Helicobacter 16: 420-426.
22. Tai WC, Chiu CH, Liang CM, Chang KC, Kuo CM, et al. (2013) Ten-day versus 14-day Levofloxacin-containing Triple Therapy for Second-line anti-Helicobacter Pylori Eradication in Taiwan. Gastroenterol Res Pract. 2013: 932478.
23. Robicsek A, Jacoby GA, Hooper DC (2006) The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 6: 629-640. (Pubitemid 44427732)
24. Su P, Li Y, Li H, Zhang J, Lin L, et al. (2013) Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter. 18: 274-279.
25. Murakami K, Furuta T, Ando T, Nakajima T, Inui Y, et al. (2013) Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylorieradication in Japan. J Gastroenterol 48: 1128-1135.
26. Kobayashi I, Murakami K, Kato M, Kato S, Azuma T, et al. (2007) Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol. 45: 4006-4010. (Pubitemid 350274884)
27. Goh KL, Navaratnam P (2011) High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia. Helicobacter 16: 241-245.
28. Wu DC, Hsu PI, Tseng HH, Tsay FW, Lai KH, et al. (2011) Helicobacter pylori infection. A randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies Medicine 90: 180-185.
29. Vakil N, Megraud F (2007) Eradication therapy for Helicobacter pylori. Gastroenterology 133: 985-1001. (Pubitemid 47374146)
30. Liou JM, Chen CC, Chang CY, Chen MJ, Fang YJ, et al. (2013). Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 68: 450-456.
31. Schabereiter-Gurtner C, Hirschl AM, Dragosics B, Hufnagl P, Puz S, et al. (2004) Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens. J Clin Microbiol 42: 4512-4518. (Pubitemid 39362364)
32. Garcia M, Raymond J, Garnier M, Cremniter J, Burucoa C (2012) Distribution of spontaneous gyrA mutations in 97 fluoroquinolone-resistant Helicobacter pylori isolates collected in France. Antimicrob Agents Chemother. 56: 550-551.
33. Liou JM, Chang CY, Sheng WH, Wang YJ, Chen MJ, et al. (2011) Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. Antimicrob Agents Chemother 55: 1123-1129.
34. Cambau E, Allerheiligen V, Coulon C, Corbel C, Lascols C, et al. (2009) Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol. 47: 3600-3607.
35. Tanimura H, Kawano S, Kubo M, Abe T, Goto M, et al. (1998) Does Helicobacter pylori eradication depend on the period of amoxicillin treatment? A retrospective study. J.Gastroenterol. 33: 23-26. (Pubitemid 28067770)
36. Hsu PI, Wu DC, Wu JY, Graham DY (2011) Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 16: 139-145.
37. Wu W, Yang Y, Sun G (2012) Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication. Gastroenterol Res Pract. 2012; 723183.
38. Bonis M, Williams A, Guadagnini S, Werts C, Boneca IG (2012) The effect of bulgecin A on peptidoglycan metabolism and physiology of Helicobacter pylori. Microb Drug Resist. 18: 230-9.
39. Qureshi NN, Morikis D, Schiller NL (2011) Contribution of specific amino acid changes in penicillin binding protein 1 to amoxicillin resistance in clinical Helicobacter pylori isolates. Antimicrob Agents Chemother. 55: 101-109.